BIOLASE, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Debt - Additional Information (Detail)

Debt - Additional Information (Detail)							1 Months Ended				9 Months Ended	12 Months Ended
Debt - Additional Information (Detail)	Nov. 18, 2021 USD ($)	Aug. 12, 2020 USD ($)	May 22, 2020 USD ($)	May 07, 2019 USD ($) shares	May 07, 2019 USD ($) shares	Nov. 09, 2018 USD ($) d $ / shares shares	Apr. 30, 2021	Mar. 31, 2020 USD ($) $ / shares shares	Nov. 30, 2019 $ / shares	Oct. 31, 2019 $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2019	Dec. 31, 2018 USD ($)	Jun. 30, 2022 USD ($)	Feb. 24, 2021 USD ($)	Feb. 10, 2021 $ / shares	Jun. 10, 2020 $ / shares shares	May 15, 2020 USD ($)	Sep. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Nov. 14, 2018 shares
Debt Instrument [Line Items]
Change in fair value of warrants												$ 0	$ 0	$ (5,850,000)
Non current term loans												13,791,000	13,603,000
Borrowings under lines of credit												0	0	3,000,000
Repayments of lines of credit												0	0	3,000,000
Debt issuance costs												$ 0	25,000	128,000
Weighted-average interest rate												11.60%
EBITDA target												$ (25,338,000)	(16,431,000)	(18,536,000)
Share price \| $ / shares																				$ 25.75
Common Stock
Debt Instrument [Line Items]
Warrants issued to purchase shares of common stock \| shares																					432,000,000
Initial exercise price of warrants \| $ / shares																					$ 12.875
Warrants Issued on November 9, 2018
Debt Instrument [Line Items]
Loan origination fee												1,400,000
SWK Warrants
Debt Instrument [Line Items]
Warrants expiration period						8 years
Warrants fair value assumptions, expected volatility rate						81.79%
Warrants fair value assumptions annual dividend per share \| $ / shares						$ 0.00
Warrants fair value assumptions, risk-free interest rate						3.13%
Change in fair value of warrants						$ 400
Warrants issued to purchase shares of common stock \| shares						372,023		487,198
Warrants expire date						Nov. 09, 2026
Initial exercise price of warrants \| $ / shares						$ 33.50		$ 9.75
Warrants adjusted strike price \| $ / shares								$ 12.25	$ 25.00	$ 1.00
Number of trading days of average closing price of common stock \| d						10
Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights \| shares								63,779
SWK Warrants \| Warrants Issued on November 9, 2018
Debt Instrument [Line Items]
Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights \| shares						372,023
DPG Warrants
Debt Instrument [Line Items]
Finder's fee						$ 500,000
Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights \| shares						279,851
BIOLASE Warrants Member
Debt Instrument [Line Items]
Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights \| shares						14,881,000,000
BIOLASE Warrants Member \| Common Stock
Debt Instrument [Line Items]
Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights \| shares				1,382	1,382																				11,194
BIOLASE Warrants Member \| Warrants Issued on May, 2019
Debt Instrument [Line Items]
Additional Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights \| shares				34,552	34,552
Credit Agreement First Amendment
Debt Instrument [Line Items]
Interest expense												800,000	200,000	300,000
Additional warrants to purchase common stock value				$ 100,000
Additional finders fee				100,000
Credit Agreement First Amendment \| SWK Warrants
Debt Instrument [Line Items]
Additional warrants to purchase common stock value				200,000
Business Financing Agreement
Debt Instrument [Line Items]
Note interest rate per annum			3.75%
Non current term loans												$ 150,000	150,000
Loan principal amount			$ 150,000
Loan periodic payment terms			installment payments, including principal and interest, are due monthly beginning in July 2021 and are payable through July 2050. In April 2021, the SBA announced that it was extending the first payment due date for all loans until 2022, or 24 months from the loan execution date. In March 2022, the SBA announced that it was extending the first payment due date for all loans an additional six months, or 30 months from the loan execution date. The Company began making payments on this EIDL Loan starting in November 2022. Fixed payments are first applied to any accrued interest.
Extension of loan due date							2022
Loan balance payment terms			payable through July 2050
Credit Agreement Ninth Amendment [Member]
Debt Instrument [Line Items]
Loan principal amount																		$ 1,000,000.0
Maximum \| SWK Warrants
Debt Instrument [Line Items]
Change in fair value of warrants								$ 100,000
Initial exercise price of warrants \| $ / shares												$ 22.00
Minimum \| SWK Warrants
Debt Instrument [Line Items]
Initial exercise price of warrants \| $ / shares												$ 33.50
Western Alliance \| Business Financing Agreement
Debt Instrument [Line Items]
Repayments of lines of credit						$ 900,000
SWK Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity																								$ 12,500,000
Interest rate						10.00%
Non current term loans												$ 14,650,000	14,300,000
Line of credit facility term						5 years
Borrowings under lines of credit						$ 14,350,000
Repayments of lines of credit						$ 700,000
Debt instrument covenant description												(i) maintain unencumbered liquid assets of (A) no less than $1.5 million or (B) the sum of aggregate cash flow from operations less capital expenditures, (ii) achieve certain revenue and EBITDA levels during the first two years of the loan, (iii) limit future borrowing, investments and dividends, and (iv) submit monthly and quarterly financial reporting.
Debt issuance costs																	$ 1,000,000.0
Interest expense												$ 2,800,000	$ 1,700,000	$ 1,800,000
SWK Loan \| Credit Agreement First Amendment
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				15,000,000.0	$ 15,000,000.0
Debt instrument covenant description																(i) adjust minimum revenue and EBITDA levels, (ii) require the Company to have a shelf registration statement declared effective by the Securities and Exchange Commission before September 30, 2019, with a proposed maximum aggregate offering price of at least $10.0 million if the Company does not reach set minimum revenue levels for the three-month period ended September 30, 2019, and (iii) require minimum liquidity of $1.5 million at all times. The First Amendment provided that if aggregate minimum revenue and EBITDA levels were not achieved by September 30, 2019, the minimum liquidity requirement would be increased to $3.0 million, until the Company has obtained additional equity or debt funding of no less than $5.0 million.
Minimum level of liquidity financial covenant				1,500,000	1,500,000
Additional equity or debt funding requirement until minimum liquidity is met				5,000,000.0	5,000,000.0
Maximum aggregate offering price					10,000,000.0
Increase in minimum liquidity requirement if aggregate minimum revenue and EBITDA levels are not achieved				3,000,000.0	3,000,000.0
Financial covenant additional borrowings				2,500,000	2,500,000
Loan origination and other fees to be paid				$ 100,000	$ 100,000
SWK Loan \| Credit Agreement, Second Amendment [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity																							$ 5,000,000
Gross proceeds from subordinated debt threshold limit											$ 5,000,000
SWK Loan \| Credit Agreement, Sixth Amendment
Debt Instrument [Line Items]
Repayments of lines of credit		$ 700,000
SWK Loan \| Credit Agreement Eighth Amendment
Debt Instrument [Line Items]
Note maturity date	May 31, 2025
Debt Instrument, Interest Rate, Basis Point	200 basis points
SWK Loan \| Maximum
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets												$ 1,500,000
SWK Loan \| Maximum \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Subordinated debt issued															$ 10,000,000.0
SWK Loan \| Maximum \| Credit Agreement, Seventh Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets																			$ 15,000,000
SWK Loan \| Maximum \| Credit Agreement Eighth Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets	$ 7,500,000
SWK Loan \| Minimum \| Credit Agreement, Fifth Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets															3,000,000.0							$ 1,500,000
Revenue target															41,000,000.0
EBITDA target															$ 7,000,000.0
SWK Loan \| Minimum \| Credit Agreement, Seventh Amendment
Debt Instrument [Line Items]
Debt instrument covenants unencumbered liquid assets																			$ 15,000,000